ADCY5 screening in paediatric-onset hyperkinetic movement disorders: Report of three new Italian families
Objective: To report three new cases with pathogenic ADCY5 mutations and describe their clinical phenotype. Background: ADCY5 is a recently identified gene responsible for a…Developing a new home monitoring device for dyskinesia in Parkinson’s disease
Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease
Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia
Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…Objective data in Parkinson’s disease therapy management – A retrospective analysis of the Parkinson’s kinetigraph (PKG) database
Objective: To assess whether patients who received a PKG analysis in routine care featured improved PD symptom scores over time using the PKG central repository.…MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…AntiParkinsonian effects of the “radiprodil and tozadenant” combination in MPTP-treated marmosets
Objective: Investigate a combination of two clinically tested drugs, the NR2B antagonist Radiprodil and the A2A antagonist Tozadenant in unilaterally 6-OHDA-lesioned rats and in MPTP-treated…Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in the management of idiopathic Parkinson’s disease: Results of our first 20 cases
Objective: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is widely accepted as a treatment for advanced Parkinson's disease (PD). However, published studies were…Monitoring dyskinesia severity using wearable sensor data
Objective: Herein we present the results of ongoing work focused on estimating limb-specific dyskinesia in patients with PD using wearable sensor data collected in the…Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets
Objective: To determine the role of M4 muscarinic receptors in the expression of L-DOPA-induced dyskinesia (LID) and dystonia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Background:…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- 40
- Next Page »